This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Jefferies Global Healthcare Conference being held June 2-5, 2014 in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Monday, June 2 at 10:30 AM (ET). Mr. Christensen will provide a corporate update on the Company’s key value drivers – the
KALBITOR® (ecallantide) business, DX-2930 and the LFRP.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at
www.dyax.com. The webcast will also be available on the Dyax website for a limited period of time following the conference.
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company currently markets KALBITOR
® for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. Dyax is also developing DX-2930 for the prophylactic treatment of HAE. Additionally, the Company has developed a biomarker assay that detects activated plasma kallikrein in blood and is being used for internal research and development efforts, including the exploration and identification of other plasma kallikrein-mediated indications beyond HAE.
Both KALBITOR and DX-2930 were identified using Dyax's patented phage display technology. Dyax has broadly licensed this technology and has a portfolio of product candidates being developed by its licensees, which it refers to as the Licensing and Funded Research Portfolio (LFRP). The Company is eligible to receive future milestones and/or royalties dependent upon the development and commercialization of these candidates. In April 2014, Dyax’s licensee Lilly received FDA approval for CYRAMZA™ (ramucirumab) as a single-agent treatment for patients with advanced gastric cancer after prior chemotherapy, making this the first approved product from Dyax’s LFRP.